GLP1R and Hyperglycemia: Considering that sitagliptin is not able to completely normalize hyperglycaemia in studies using low doses [8, 103, 126], an alternative mechanism for the beneficial effect on kidney function/lesions can occur by a direct tissue DPP-4 inhibition, via GLP-1-dependent and/or GLP-1-independent pathways.